Pharmacogenetics and pharmacogenomics are areas of rapidly growing importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the findings that have already emerged. Coverage extends to antipsychotics, antidepressants, mood stabilizing, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore an essential reference for all clinicians and researchers working in this field.